EC Neurology

Case Series Volume 15 Issue 6 - 2023

Security in Anti-CGRP Switch after Hypersensitivity Reactions

Cristina Cordero Sánchez*, Lucía Fabiá Polo, María Barcenilla López, Nora de La Cruz Fernández, Erika María Beck Román and Javier Casas Limón

Neurologist , Hospital Universitario Fundación Alcorcón, Spain

*Corresponding Author: Cristina Cordero Sánchez, Neurologist , Hospital Universitario Fundación Alcorcón, Spain.
Received: May 22, 2023; Published: May 31, 2023



Introduction: Migraine is globally the second cause of disability. Recently, there have been developed new treatments against calcitonin gene-related peptide (CGRP).

Cases: We present two patients who have developed allergic reactions to anti-CGRP, causing its suspension. 

Discussion: Erenumab in the majority of cases is well tolerated, although there are some reports of severe hypersensitivity reactions. 

Nowadays, in clinical practice there is an anti-CGRP switch due to lack of response. 

Conclusion: We propose, anti-CGRP switch after hypersensibility reaction, with assessment by the Allergology service.

Keywords: Anti-Cgrp Switch; Hypersensitivity Reactions; DALYs (Disability Adjusted Life Years); Calcitonin Gene-Related Peptide (CGRP)

Cristina Cordero Sánchez., et al. “Security in Anti-CGRP Switch after Hypersensitivity Reactions”. EC Neurology  15.6 (2023): 61-63.